Takeda eyes an FDA run for its investigational psoriasis pill after the drug elicited total skin clearance in more than 35% ...
The discontinuation of Sanofi’s Phase 3 study for its complement inhibitor drug in chronic inflammatory demyelinating polyneuropathy delivers an ‘obviously disappointing’ blow to the broader drug ...
Parabilis has shattered Kailera’s recently-set IPO high, raising a record-breaking $670 million. The Nasdaq debut surpasses even Parabilis’ expectations, with the peptide biotech announcing plans ...
The public biotech universe has shrunk by more than 20% since 2021, yet financial stress remains entrenched across the sector, according to a report from EY Tuesday. Hundreds of public biotech ...
Good Days, the nation’s leading nonprofit patient assistance charity, will host the Chronic Disease Day Leadership Luncheon ...
Analysts and investors were unimpressed by Phase 2 data posted in the spring showing that an amylin analog developed by Roche ...
The FDA must provide consistent and predictable regulatory frameworks if the U.S. is to maintain its leadership in gene ...
The American Diabetes Association’s annual congress will feature a superstar lineup, including weight loss giants Eli Lilly and Novo Nordisk. But several scrappy biotechs will also present obesity ...
After discontinuing development of its lead asset, Fulcrum Therapeutics has provided more details on its restructure, with 48 of 57 employees headed out the door. Fulcrum Therapeutics’ restructure ...
Otsuka Pharmaceuticals’ APRIL inhibitor Voyxact stabilized kidney function decline in a late-stage IgA nephropathy study—findings analysts say could have broader implications across the drug class, ...
The FDA hasn’t been transparent and open enough with how it has implemented the Commissioner’s National Priority Voucher program, patient, industry and trade groups said Thursday. Several ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results